



Name	KIM Hak Jae
Affiliation	Seoul National University Hospital
Country	Republic of Korea
Major Field	Radiation Oncology

Educational Background

1993 - 1999	Bachelor, College of Medicine, Seoul National University (Medicine)
2000 - 2002	Master, Graduate School, Seoul National University (Radiation Oncology)
2003 - 2010	Ph.D, Graduate School, Seoul National University (Radiation Oncology)

Professional Experience

1999 - 2000	Intern, Seoul National University Hospital
2000 - 2004	Resident, Seoul National University Hospital
2007 - 2008	Fellow, Seoul National University Bundang Hospital
2008 - 2012	Assistant clinical professor, Seoul National University Hospital
2013 - 2018	Associate professor, Seoul National University college of Medicine
2019 -	Professor, Seoul National University college of Medicine

Main Scientific Publications

- Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: A multicenter retrospective study (KROG 21-10). Song JY, Moon SH, Suh YG, Kim JH, Oh D, Noh JM, Jeong JU, Cho IJ, Kang MK, Kim JH, Kim YS, Kim HJ, Park WY, Kim BH, Kim HJ. *Radiother Oncol.* 2023 Dec;189:109936
- No survival benefit with early incorporation of thoracic radiotherapy using daily fractionation in patients with limited-stage small cell lung cancer undergoing chemoradiotherapy in the modern era: A systematic review and meta-analysis. Kim BH, Song C, Kim HJ. *Radiother Oncol.* 2023 Jul;184:109696
- Effect of Lactobacillus Rhamnosus GG for Regulation of Inflammatory Response in Radiation-Induced Enteritis. Lee SU, Jang BS, Na YR, Lee SH, Han S, Chang JH, Kim HJ. *Probiotics Antimicrob Proteins.* 2023 Apr 18
- Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer. Lee TH, Chung JH, Wu HG, Kim S, Lee JH, Keam B, Kim JS, Kim KH, Kim BH, Kim HJ. *Cancer Res Treat.* 2023 Jul;55(3):875-884
- Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09). Lee TH, Shin H, Ahn YC, Kang MK, Song C, Kim WC, Moon SH, Kim JH, Cho J, Park HJ, Lee HK, Kim BH, Kim HJ. *Radiother Oncol.* 2023 Jun;183:109572
- Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy. Kim BH, Chung JH, Son J, Kim S, Wu HG, Kim HJ. *Cancer Res Treat.* 2023 Jan;55(1):73-82
- Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Lee TH, Kim HJ, Kim BH, Kang CH, Keam B, Moon HJ, Seong YW, Kim S. *J Oncol*



Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024

Grand Walkerhill Seoul, Korea

"Pioneering the future of digestive diseases"



SIDDS 2024

8. Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging. Lim YJ, Song C, Kim HJ; Korean Association for Lung Cancer; Korea Central Cancer Registry. *Radiat Oncol.* 2022 Feb 5;17(1):26
9. Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis. Lee TH, Kim DY, Wu HG, Lee JH, Kim HJ. *Radiat Oncol.* 2021 Nov 18;16(1):222
10. Comparison of endoscopically determined gross tumor volume and metabolic tumor volume in esophageal cancer. Lee TH, Ryoo HG, Lee R, Paeng JC, Chung H, Kim HJ. *Medicine (Baltimore).* 2021 Jun 18;100(24):e26338